Exhibit 10.34
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [*****]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
AMENDMENT NO. 4
TO THE
SERVICES AGREEMENT
between
LONZA BIOLOGICS PLC
and
XCYTE THERAPIES, INC.
RELATING TO [**]
THIS AMENDMENT is made the 30th day of September 2002.
BETWEEN
1. | Lonza Biologics plc of 228 Bath Road, Slough, Berkshire SL1 4DY, England (“Biologics”) and |
2. | Xcyte Therapies Inc. of 1124 Columbia Street, Suite 130, Seattle, Washington 98104, USA (“Customer”). |
WHEREAS
A. | The parties have entered into an Agreement dated 6th June 2000 relating to the supply of Services (as therein defined), and |
B. | The parties now wish to amend the terms of the Agreement |
THEREFORE it is hereby agreed by and between the parties that the Agreement shall be amended as follows: -
1. | Stage 19 shall be added to Schedule 2 as follows: |
19.0 | Stage 19 – [**] |
19.1 | Objectives |
19.1.1 | Carry out a series of [**] to provide material for [**]. |
19.1.2 | Carry out work to improve the [**] for the clarification of cell line [**], using material from [**]. |
19.2 | Activities |
19.2.1 | Recover [**] from the WCB and [**] to prepare a [**]. [**] to [**] and carry out [**]. |
19.2.2 | Evaluate a range of [**] at [**] for clarification of the [**]. Identify a suitable [**] for further evaluation at [**] or [**]. |
19.2.3 | Further refine [**] of the [**] process, including the [**]. |
19.2.4 | Measure [**] across [**]. |
19.2.5 | Review requirements (if any) for [**] that may be needed following this study. Any such [**] are subject to agreement. |
2
[*] | Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. |
19.2.6 | Revise [**] for use in [**], as appropriate. |
19.2.7 | Produce a [**] detailing the [**] evaluations performed. |
19.3 | Timescale |
Stage 19 shall commence upon recovery of a [**] from the WCB. The stage shall be complete with the issue of the summary report and it is estimated that this report will be issued within [**] from the start of the Stage.” |
2. | Schedule 3, Part 1 shall be amended as follows: |
“19 [**]” |
3. | Schedule 3, Part 2 Price shall be amended as follows: |
“For Stage 19, [**] of the price on commencement of Stage 19 and [**] upon completion of Stage 19.” |
As witness the hands of the duly authorized representatives of the parties hereto, the day and year first before written. |
Signed by | ||
for and behalf of Xcyte Therapies Inc. | /s/ Ronald J. Berenson | |
Signed by | ||
for and behalf of Lonza Biologics plc. | /s/ Judith Symes |
3
[*] | Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. |